Determinants for the prognosis of acute renal disorders that developed during or after treatment with edaravone.
BACKGROUND
Edaravone, a drug for treating acute ischemic stroke, has been reported to provoke acute renal disorders. In the previous study, the author evaluated the role of edaravone in the development of renal disorders in 207 patients reported as having developed them in the post-marketing survey of the drug. The overall recovery rate of renal function in the survey was 43%. Risk factors that affect the recovery rate of renal function and mortality remain to be clarified.


METHODS
The recovery rate of renal function and mortality rate were examined according to the extent of edaravone involvement in renal disorder onset, which was defined by the concurrence of other risk factors for renal disorders, in previously reported 207 patients. Risk factors for the nonrecovery of renal function and death were determined by using a stepwise logistic regression analysis.


RESULTS
The recovery rate of renal function was low and mortality rate was high in the group where the above extent of edaravone involvement was slight. The above analysis showed that risk factors for the nonrecovery of renal function were the complication of severe infection and the implementation of blood purification, and that risk factors for death were advanced age (> or =80 years) and the complication of severe infection.


CONCLUSIONS
The nonrecovery rate of renal function and mortality rate were high in the cases of patients that were complicated with factors that affected renal function other than edaravone. The complication of severe infection was a risk factor for the nonrecovery of renal function and for death.
Hishida
Akira
A
First Department of Medicine, Hamamatsu University School of Medicine, 1-20-1, Handayama, Higashi-ku, Hamamatsu, Shizuoka, 431-3192, Japan. ahishida@hama-med.ac.jp.
D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000401:mortality*; D000983:Antipyrine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D002545:Brain Ischemia / Q000188:drug therapy / Q000401:mortality; D000077553:Edaravone; D016166:Free Radical Scavengers / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D016015:Logistic Models; D011379:Prognosis; D020127:Recovery of Function; D012307:Risk Factors; D020521:Stroke / Q000188:drug therapy* / Q000401:mortality*; D015996:Survival Rate
D016166:Free Radical Scavengers; D000077553:Edaravone; D000983:Antipyrine